SELECTIVE ANTICANCER CHIMERIC PEPTIDE

It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel...

Full description

Saved in:
Bibliographic Details
Main Authors KAWAKAMI KOJI, HORIBE TOMOHISA, YANG LIYING, NAKAJIMA OUMI, HARAMOTO MARI, KOHNO MASAYUKI
Format Patent
LanguageEnglish
Published 17.10.2013
Subjects
CHEMISTRY
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
Online AccessGet full text

Cover

More Information
Summary:It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
Bibliography:Application Number: US201313857754